Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib with Azacitidine and Venetoclax for Relapsed AML Post-HSCT
NCT06783790Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of avapritinib in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jan 2025; status: recruiting.
02
Drugs
avapritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06783790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06783790.